# Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

> **NCT01686386** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Gruppo Italiano Studio Linfomi** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01686386
- **Lead sponsor:** Gruppo Italiano Studio Linfomi
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-02
- **Primary completion:** 2012-04
- **Final completion:** 2013-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01686386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01686386, "Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01686386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*